» Articles » PMID: 19669109

Extended Nitric Oxide Measurements in Exhaled Air of Cystic Fibrosis and Healthy Adults

Overview
Journal Lung
Specialty Pulmonary Medicine
Date 2009 Aug 12
PMID 19669109
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

In cystic fibrosis (CF) lung disease, exhaled nitric oxide (FeNO) is not raised, but rather is normal or even decreased when measured at a single expiratory flow. FeNO measurements at several flow rates allow differentiation between alveolar and bronchial nitric oxide (NO) production. Extended FeNO measurements therefore should be useful to localize the FeNO deficit in CF airways. FeNO was measured in stable CF adults with moderate lung disease and in healthy controls. Bronchial NO fluxes (J(NO,Br)) and alveolar NO concentrations (C(Alv)) were calculated from FeNO measurements at flow rates of 100, 150 and 200 ml/s using a method previously described. Thirty-two adults were included in the study, 12 of whom had CF. CF adults had significantly lower FeNO values at all flow rates. The median J(NO,Br) was significantly lower in CF adults than in healthy controls [0.31 nl/s (range = 0.11-0.63) vs. 0.70 nl/s (0.27-3.52); P < 0.001], while the median C(Alv) was similar in both groups [1.7 ppb (0.3-3.9) vs. 1.2 (0.1-5.2)]. Pulmonary NO exchange did not differ significantly between subgroups of CF patients with and without chronic Pseudomonas aeruginosa infection. No significant correlation was detectable between FEV(1)/VC and J(NO,Br) and C(Alv), respectively. Extended FeNO measurements can separate alveolar and bronchial NO outputs in CF adults. The lower FeNO in adults with moderate to severe CF lung disease is likely to be the result of lower bronchial NO output.

Citing Articles

Exhaled Biomarkers for Point-of-Care Diagnosis: Recent Advances and New Challenges in Breathomics.

Kiss H, Orlos Z, Gellert A, Megyesfalvi Z, Mikaczo A, Sarkozi A Micromachines (Basel). 2023; 14(2).

PMID: 36838091 PMC: 9964519. DOI: 10.3390/mi14020391.


Application of nitric oxide measurements in clinical conditions beyond asthma.

Malinovschi A, Ludviksdottir D, Tufvesson E, Rolla G, Bjermer L, Alving K Eur Clin Respir J. 2015; 2:28517.

PMID: 26672962 PMC: 4653314. DOI: 10.3402/ecrj.v2.28517.


Assessment of health effects related to fiber glass exposure in fiber glass workers: exhaled biomarkers eCO, FENO and their usefulness in the occupational environment testing.

Domokos Hancu B, Pop M Clujul Med. 2015; 86(2):114-6.

PMID: 26527930 PMC: 4462426.


Evaluation of exhaled nitric oxide in acute paraquat poisoning: a pilot study.

Choi S, Oh S, Min Y, Cha J, Gil H, Hong S Med Sci Monit. 2014; 20:167-72.

PMID: 24487780 PMC: 3914929. DOI: 10.12659/MSM.889820.


Using bacterial biomarkers to identify early indicators of cystic fibrosis pulmonary exacerbation onset.

Rogers G, Hoffman L, Johnson M, Mayer-Hamblett N, Schwarze J, Carroll M Expert Rev Mol Diagn. 2011; 11(2):197-206.

PMID: 21405970 PMC: 3148893. DOI: 10.1586/erm.10.117.

References
1.
Grasemann H, Lax H, Treseler J, Colin A . Dornase alpha and exhaled NO in cystic fibrosis. Pediatr Pulmonol. 2004; 38(5):379-85. DOI: 10.1002/ppul.20088. View

2.
Pietropaoli A, Perillo I, Torres A, PERKINS P, Frasier L, Utell M . Simultaneous measurement of nitric oxide production by conducting and alveolar airways of humans. J Appl Physiol (1985). 1999; 87(4):1532-42. DOI: 10.1152/jappl.1999.87.4.1532. View

3.
. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med. 2005; 171(8):912-30. DOI: 10.1164/rccm.200406-710ST. View

4.
Lundberg J, Nordvall S, Weitzberg E, Kollberg H, Alving K . Exhaled nitric oxide in paediatric asthma and cystic fibrosis. Arch Dis Child. 1996; 75(4):323-6. PMC: 1511735. DOI: 10.1136/adc.75.4.323. View

5.
Ratjen F, Doring G . Cystic fibrosis. Lancet. 2003; 361(9358):681-9. DOI: 10.1016/S0140-6736(03)12567-6. View